Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells.

Bellissimo T, Tito C, Ganci F, Sacconi A, Masciarelli S, Di Martino G, Porta N, Cirenza M, Sorci M, De Angelis L, Rosa P, Calogero A, Fatica A, Petrozza V, Fontemaggi G, Blandino G, Fazi F.

Cell Death Dis. 2019 Jan 8;10(1):17. doi: 10.1038/s41419-018-1267-5.

2.

Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.

Donzelli S, Milano E, Pruszko M, Sacconi A, Masciarelli S, Iosue I, Melucci E, Gallo E, Terrenato I, Mottolese M, Zylicz M, Zylicz A, Fazi F, Blandino G, Fontemaggi G.

Breast Cancer Res. 2018 Jun 19;20(1):59. doi: 10.1186/s13058-018-0990-2.

3.

Zebrafish as experimental model to establish the contribution of mutant p53 and ID4 to breast cancer angiogenesis in vivo.

Pruszko M, Milano E, Zylicz A, Zylicz M, Blandino G, Fontemaggi G.

J Thorac Dis. 2018 Mar;10(3):E231-E233. doi: 10.21037/jtd.2018.03.86. No abstract available.

4.

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Di Agostino S, Valenti F, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, Ganci F, Muti P, Strano S, Blandino G.

Theranostics. 2018 Feb 12;8(7):1850-1868. doi: 10.7150/thno.22167. eCollection 2018.

5.

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.

Masciarelli S, Capuano E, Ottone T, Divona M, De Panfilis S, Banella C, Noguera NI, Picardi A, Fontemaggi G, Blandino G, Lo-Coco F, Fazi F.

Leukemia. 2018 Feb;32(2):285-294. doi: 10.1038/leu.2017.231. Epub 2017 Aug 4.

6.

Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence.

Ganci F, Sacconi A, Manciocco V, Covello R, Benevolo M, Rollo F, Strano S, Valsoni S, Bicciato S, Spriano G, Muti P, Fontemaggi G, Blandino G.

Mod Pathol. 2017 Oct;30(10):1387-1401. doi: 10.1038/modpathol.2017.62. Epub 2017 Jul 21.

7.

The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.

Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, De Panfilis S, Fazi F, Bates DO, Bicciato S, Zylicz M, Zylicz A, Blandino G, Fontemaggi G.

EMBO Rep. 2017 Aug;18(8):1331-1351. doi: 10.15252/embr.201643370. Epub 2017 Jun 26.

8.

Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition.

Fontemaggi G, Bellissimo T, Donzelli S, Iosue I, Benassi B, Bellotti G, Blandino G, Fazi F.

RNA Biol. 2015;12(7):690-700. doi: 10.1080/15476286.2015.1044194.

9.

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.

Valenti F, Ganci F, Fontemaggi G, Sacconi A, Strano S, Blandino G, Di Agostino S.

Oncotarget. 2015 Mar 20;6(8):5547-66.

10.

MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma.

Ganci F, Sacconi A, Manciocco V, Sperduti I, Battaglia P, Covello R, Muti P, Strano S, Spriano G, Fontemaggi G, Blandino G.

Head Neck. 2016 Apr;38 Suppl 1:E189-97. doi: 10.1002/hed.23969. Epub 2015 Jun 24.

PMID:
25532855
11.

Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells.

Iosue I, Quaranta R, Masciarelli S, Fontemaggi G, Batassa EM, Bertolami C, Ottone T, Divona M, Salvatori B, Padula F, Fatica A, Lo-Coco F, Nervi C, Fazi F.

Cell Death Dis. 2013 Nov 21;4:e926. doi: 10.1038/cddis.2013.452.

12.

Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G, Blandino G.

Ann Oncol. 2013 Dec;24(12):3082-8. doi: 10.1093/annonc/mdt380. Epub 2013 Oct 9.

13.

The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination.

Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Yarden Y, Domany E, Blandino G.

Cell Cycle. 2013 Aug 1;12(15):2371-5. doi: 10.4161/cc.25380. Epub 2013 Jun 26. Review.

14.

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.

Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G.

Oncogene. 2014 Mar 20;33(12):1601-8. doi: 10.1038/onc.2013.106. Epub 2013 Apr 15.

PMID:
23584479
15.

ChIP-on-chip to identify mutant p53 targets.

Goeman F, Fontemaggi G, Blandino G.

Methods Mol Biol. 2013;962:211-26. doi: 10.1007/978-1-62703-236-0_18.

PMID:
23150450
16.

miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours.

Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E, Blandino G.

EMBO Mol Med. 2012 Nov;4(11):1214-29. doi: 10.1002/emmm.201201483.

17.

MicroRNAs and lymph node metastatic disease in lung cancer.

Fazi F, Fontemaggi G.

Thorac Surg Clin. 2012 May;22(2):167-75. doi: 10.1016/j.thorsurg.2011.11.001. Epub 2011 Dec 27. Review.

PMID:
22520284
18.

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G.

Cell Death Differ. 2012 Jun;19(6):1038-48. doi: 10.1038/cdd.2011.190. Epub 2011 Dec 23.

19.

Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S.

Cell Cycle. 2011 Dec 15;10(24):4330-40. doi: 10.4161/cc.10.24.18682. Epub 2011 Dec 15.

PMID:
22134238
20.

Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.

Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S, Blandino G, Spriano G.

OMICS. 2011 Jun;15(6):375-81. doi: 10.1089/omi.2010.0142. Epub 2011 Feb 24.

PMID:
21348641
21.

ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.

Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G.

OMICS. 2011 May;15(5):305-12. doi: 10.1089/omi.2010.0084. Epub 2011 Feb 19.

PMID:
21332394
22.

ID4: a new player in the cancer arena.

Dell'Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G.

Oncotarget. 2010 May;1(1):48-58.

23.

Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1.

Fontemaggi G, Dell'Orso S, Muti P, Blandino G, Strano S.

Cell Cycle. 2010 Jun 15;9(12):2464-6. Epub 2010 Jun 15. No abstract available.

PMID:
20519942
24.

Modulation of the vitamin D3 response by cancer-associated mutant p53.

Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V.

Cancer Cell. 2010 Mar 16;17(3):273-85. doi: 10.1016/j.ccr.2009.11.025. Erratum in: Cancer Cell. 2010 May 18;17(5):523. Sigfried, Zahava [corrected to Siegfried, Zehava].

25.

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G.

Nat Struct Mol Biol. 2009 Oct;16(10):1086-93. doi: 10.1038/nsmb.1669. Epub 2009 Sep 27.

PMID:
19783986
26.

Oncogenomic Approaches in Exploring Gain of Function of Mutant p53.

Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G.

Curr Genomics. 2008 May;9(3):200-7. doi: 10.2174/138920208784340713.

27.

deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation.

Mainardi S, Pelosi A, Palescandolo E, Riccioni R, Fontemaggi G, Diverio D, Testa U, Sacchi A, Grignani F, Lo-Coco F, Levrero M, Blandino G, Rizzo MG.

Cell Death Differ. 2007 Nov;14(11):1968-71. Epub 2007 Aug 10. No abstract available.

28.

Mutant p53: an oncogenic transcription factor.

Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G.

Oncogene. 2007 Apr 2;26(15):2212-9. Review.

PMID:
17401430
29.

Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.

Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M.

Cancer Res. 2007 Mar 15;67(6):2396-401. Erratum in: Cancer Res. 2015 Sep 3;:null.

30.

Mutant p53 proteins: between loss and gain of function.

Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, Fontemaggi G, Blandino G.

Head Neck. 2007 May;29(5):488-96. Review.

PMID:
17123310
31.

S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation.

Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G, Strano S.

Oncogene. 2006 Jun 22;25(26):3628-37. Epub 2006 Jan 30.

PMID:
16449968
32.

deltaEF1 repressor controls selectively p53 family members during differentiation.

Fontemaggi G, Gurtner A, Damalas A, Costanzo A, Higashi Y, Sacchi A, Strano S, Piaggio G, Blandino G.

Oncogene. 2005 Nov 10;24(49):7273-80.

PMID:
16007124
33.

The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage.

Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, Blandino G.

Mol Cell. 2005 May 13;18(4):447-59. Erratum in: Mol Cell. 2005 Aug 5;19(3):429.

34.

Physical and functional interaction between HCV core protein and the different p73 isoforms.

Alisi A, Giambartolomei S, Cupelli F, Merlo P, Fontemaggi G, Spaziani A, Balsano C.

Oncogene. 2003 May 1;22(17):2573-80.

PMID:
12730672
35.

Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses.

Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, Blandino G.

J Biol Chem. 2002 Nov 8;277(45):43359-68. Epub 2002 Sep 3.

36.

Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.

Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G.

J Biol Chem. 2002 May 24;277(21):18817-26. Epub 2002 Mar 13.

37.

DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes.

Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M.

Mol Cell. 2002 Jan;9(1):175-86.

38.

The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation.

Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, Blandino G.

Mol Cell Biol. 2001 Dec;21(24):8461-70.

39.

The cyclin B1 gene is actively transcribed during mitosis in HeLa cells.

Sciortino S, Gurtner A, Manni I, Fontemaggi G, Dey A, Sacchi A, Ozato K, Piaggio G.

EMBO Rep. 2001 Nov;2(11):1018-23. Epub 2001 Oct 17.

40.

Absence of in vivo DNA-protein interactions in the DQA2 and DQB2 promoter regions.

Indovina P, Megiorni F, Fontemaggi G, Coni P, Mora B, Mazzilli MC.

Hum Immunol. 2001 May;62(5):504-8.

PMID:
11334674
41.

From p63 to p53 across p73.

Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A, Blandino G.

FEBS Lett. 2001 Feb 16;490(3):163-70. Review.

42.

p53 regulates myogenesis by triggering the differentiation activity of pRb.

Porrello A, Cerone MA, Coen S, Gurtner A, Fontemaggi G, Cimino L, Piaggio G, Sacchi A, Soddu S.

J Cell Biol. 2000 Dec 11;151(6):1295-304.

43.

Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells.

Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, Piaggio G, Sacchi A, Pontecorvi A, Bacchetti S, Farsetti A.

Mol Cell Biol. 2000 Jun;20(11):3764-71.

44.

Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex.

Farina A, Manni I, Fontemaggi G, Tiainen M, Cenciarelli C, Bellorini M, Mantovani R, Sacchi A, Piaggio G.

Oncogene. 1999 May 6;18(18):2818-27.

Supplemental Content

Loading ...
Support Center